This news release was originally published on the Department of Defense's website.

The Department of Defense, in coordination with the Department of Health and Human Services, awarded two contract modifications totaling $3.2 billion to Regeneron Pharmaceuticals, Inc. and Eli Lilly and Company to purchase additional doses of monoclonal antibodies to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.